People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| General Oncology, Inc. | — | Pharmaceuticals | Series B | $45.7M | $369.9M | 2019 |
Jeffrey Aaron Glazier at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Aaron Glazier on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael J. Petit | 1 | 2 |
| Gregg Goldstein | 1 | 2 |
| Henry Esber | 1 | 2 |
| Abid J. Ansari | 1 | 1 |
| Barry J. Seeman | 1 | 1 |
| Michael D. Sigman | 1 | 1 |
| Arnold Glazier | 1 | 1 |
| Arnold Aaron Glazier | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.